Sanofi, Dupixent and Regeneron
Clayton Dubilier & Rice made it a condition for banks to commit more than €1 billion ($1.1 billion) of debt to fund a part of ...
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...
China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...
Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...
Sanofi's (SNY) plans to seperate its consumer care unit draws buyout bids with over €10B in funding committed from banks and ...
Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback